Recent research indicates that semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, could be produced for a mere $3 per month. This significant reduction in potential cost may revolutionise access to vital medications for millions suffering from obesity and diabetes, particularly in lower-income nations.
A New Hope for Millions
Over a billion individuals globally grapple with obesity, a figure that is surging, especially in developing countries that are increasingly adopting Western dietary patterns and sedentary lifestyles. In September 2022, the World Health Organization (WHO) classified semaglutide as an essential medicine, highlighting its importance in combating these pressing health issues. However, the high cost of this treatment has hindered access for many, prompting calls for more affordable solutions.
Newly released findings suggest that with the expiration of key patents, semaglutide could be manufactured at a fraction of its current price. According to a pre-print study, the injectable form of the drug could be made available for just $3 (approximately £2.35) monthly, while oral versions may be produced for around $16 each month. Dr Andrew Hill from the University of Liverpool, one of the study’s authors, remarked, “These low prices open the door to worldwide access to an essential medicine.”
Patent Expirations and Global Access
The research outlines a promising landscape for the availability of semaglutide, particularly as patents are set to expire in ten countries by March 21, including major economies like Brazil, China, and India. Furthermore, the study identifies 150 additional countries where patents have not been filed, encompassing much of Africa. These 160 nations are home to 69% of individuals living with type 2 diabetes and 84% of those classified as obese.
Prof François Venter from the University of Witwatersrand in Johannesburg echoed the potential impact: “Drugs to treat HIV, TB, malaria, and hepatitis are already accessible in low- and middle-income countries at prices close to production costs, saving millions of lives. We can replicate this success story for semaglutide.”
Addressing Structural Barriers
Despite the promising news regarding the affordability of semaglutide, experts caution that simply providing cheaper medications will not solve the underlying issues driving obesity. Dr Nomathemba Chandiwana, Chief Scientific Officer at South Africa’s Desmond Tutu Health Foundation, stressed the need for coordinated policies to integrate these drugs into broader healthcare strategies addressing obesity and diabetes. “This could be very significant for South Africa and many other African countries,” she noted, highlighting that approximately 27% of adults globally meet the criteria for medications like semaglutide, with a significant proportion residing in low- and middle-income countries.
The relationship between obesity and various health complications—including heart disease, diabetes, and certain cancers—underscores the urgency of addressing this health crisis. Current statistics reveal a staggering increase in diabetes prevalence, rising from 200 million cases in 1990 to 830 million in 2022, with the most drastic increases observed in lower-income regions.
Costs and Future Perspectives
Semaglutide, first approved by US regulators in 2017, currently retails for about $200 per month in the United States and £120 in the United Kingdom, with patents in these regions not set to expire for another five years. The implications of the recent research are vast, suggesting a potential shift towards lower costs for essential medications, particularly for chronic conditions that disproportionately affect vulnerable populations.
Utilising shipment records for key ingredients and leveraging methodologies proven effective in predicting prices for generic medicines, the study paints a hopeful future. Following prior research from Médecins Sans Frontières, which indicated that diabetes medications could be produced more economically, the findings bolster the case for affordable healthcare solutions worldwide.
Why it Matters
The ability to produce semaglutide at a significantly reduced cost could be transformative for public health, particularly in low and middle-income countries where access to essential medicines is severely restricted. By alleviating the financial burden associated with obesity and diabetes treatment, we can expect to see not only improved health outcomes but also a broader societal impact, as millions gain access to life-saving medications. As the world continues to battle rising obesity rates and associated health crises, the integration of affordable treatments into healthcare frameworks is critical for fostering healthier communities and reducing healthcare disparities.
